Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026

Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa

Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion

UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers

Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement.

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Vor Bio Announces $75 Million Private Placement with TCGX

Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseases

GSK enters agreement to acquire RAPT Therapeutics

Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Cogent Biosciences Reports Positive Phase 3 trial in GIST

BioCryst to Acquire Astria Therapeutics

Announces Oversubscribed $1.3B TCGX Fund III

Novartis to acquire Tourmaline Bio

Next-generation vaccine biotech, to be acquired by Sanofi for US$1.6 billion

Adcendo Completes Oversubscribed $135 Million Series B Financing

Vicebio Announces $100 Million Series B…

Candid Therapeutics Debuts with $370M Capital Raise

Beacon Therapeutics Raises $170 Million in Series B Funding

Geron Announces FDA Approval of Rytelo imetelstat

Announces $120m Series B financing to fund development of its differentiated ADC pipeline

Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Announces $120 Million Private Placement Financing

Announces Oversubscribed $120 Million Private Placement

Announces $127.5 Million Private Placement Financing

Announces Pricing Of $125 Million Underwritten Offering

Announces Pricing of Upsized Initial Public Offering

Announces Pricing of $240 Million Underwritten Offering of Common Stock

TCG Crossover (“TCGX”) Announces Oversubscribed $1B TCGX Fund II

To be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases

Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca

Carmot Therapeutics Enters into Definitive Merger Agreement with Roche

Vistagen Announces Pricing of $100 Million Underwritten Offering

Structure Therapeutics Announces $300 Million Private Placement Equity Financing

COMPASS Pathways Announces Up to $285 Million Private Placement Financing

AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock

Taysha Gene Therapies Announces $150 Million Private Placement Financing

ADARx Pharmaceuticals Announces Oversubscribed $200 Million Series C Financing

Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing

Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases

Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock

Upstream Bio Announces $200M Series B Financing

Alkeus Announces $150 Million Series B Financing

Carmot Therapeutics Raises $150 Million in Series E

Ironwood Enters into Definitive Agreement to Acquire VectivBio

Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock

Astellas Enters Into Definitive Agreement to Acquire Iveric Bio

Madrigal Announces Positive Topline Results from the Pivotal Phase 3

Geron Announces Positive Top-Line Results from IMerge Phase 3

Abivax announces successful oversubscribed EUR 130M cross-over financing

Structure Therapeutics Announces Pricing of Upsized Initial Public Offering

VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares

Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock

Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock

Abivax announces successful oversubscribed EUR 49.2M cross-over financing

Upstream Bio Launches with $200M Series A

Plexium Announces $102M Financing

Eikon Therapeutics Announces $517.8 Million Series B Raise

Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing

Entrada Therapeutics Announces Pricing of Upsized Initial Public Offering

ShouTi Secures $100 Million Series B Financing

Obsidian Therapeutics Announces Closing of $115 Million Series B Financing

Artios Announces $153 Million Series C Financing

RayzeBio Secures $108 Million Series C Financing

Synthekine Announces $107.5 Million Oversubscribed Series B Financing

Affinia Therapeutics Closes $110 Million Series B Financing

TCG X Raises Inaugural $824 Million Fund to Advance Disruptive Medicines

Entrada Therapeutics Announces Closing of $116 Million Series B Financing

Aktis Oncology Announces $72 Million Series A Financing to Advance Breakthrough Radiopharmaceuticals